Regeneron Reports Second Quarter 2022 Financial and Operating Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. CART
8. LLY
9. TSLA
10. FICO

Go back to Regeneron Reports Second Quarter 2022 Financial and Operating Results

Oppenheimer Positive on Regeneron Pharma (REGN), 'We anticipate material pipeline readouts in 2H22/1H23'

August 4, 2022 10:21 AM EDT

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $775.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst comments "Regeneron (REGN) reported 2Q22 sales/earnings on 8/3 and provided a business update. Sales modestly outpaced OPCO expectations while earnings beat our estimates by... More

Regeneron (REGN) Tops Q2 EPS by $1.17

August 3, 2022 6:38 AM EDT

Regeneron (NASDAQ: REGN) reported Q2 EPS of $9.77, $1.17 better than the analyst estimate of $8.60. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.79 billion.

For earnings history and earnings-related data on Regeneron (REGN) click here.

... More